



CD115 Antibody [AFS98] (FITC)

CATALOG NUMBER: 76-877

Specifications

SPECIES REACTIVITY:	Mouse
TESTED APPLICATIONS:	FACS
USER NOTE:	Optimal dilutions for each application to be determined by the researcher.
SPECIFICITY:	The AFS98 monoclonal antibody specifically reacts with the mouse CD115 molecule, a 150 kDa receptor for the colony stimulating factor (CSF-1) or macrophage CFS (M-CFS), expressed by some epithelial cells, monocytes, osteoclasts, and macrophages.
HOST SPECIES:	Rat

Properties

PURIFICATION:	The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
PHYSICAL STATE:	liquid
BUFFER:	Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.
CONCENTRATION:	0.5 mg/mL
STORAGE CONDITIONS:	The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze.
CLONALITY:	Monoclonal
ISOTYPE:	Rat IgG2a, kappa
CONJUGATE:	FITC

Additional Info

ALTERNATE NAMES:	Fms, CD115, Csfmr, Fim-2, CSF-1R, M-CSFR, M-CSF-R, AI323359, Csf1r
OFFICIAL SYMBOL:	Csf1r
GENE ID:	12978

Background

BACKGROUND:	The AFS98 monoclonal antibody specifically reacts with the mouse CD115 molecule, a 150 kDa receptor for the colony stimulating factor (CSF-1) or macrophage CFS (M-CFS), expressed by some epithelial cells, monocytes, osteoclasts, and macrophages. The colony stimulating factor-1 regulates the proliferation and the differentiation of the monocytic lineage cells. The AFS98 antibody can be used to identify myeloid lineage cells.
REFERENCES:	<p>1) Murayama, T., Yokode, M., Kataoka, H., Imabayashi, T., Yoshida, H., Sano, H., ... Kita, T. (1999). Intraperitoneal administration of anti-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E deficient mice. <i>Circulation</i>, 99(13), 1740-1746.</p> <p>2) Sudo, T., Nishikawa, S., Ogawa, M., Kataoka, H., Ohno, N., Izawa, A., Hayashi, S. (1995). Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M. <i>Oncogene</i>, 11(12), 2469-2476.</p> <p>3) Yoshino, M., Yamazaki, H., Yoshida, H., Niida, S., Nishikawa, S. I., Ryoke, K., ... Hayashi, S. I. (2003). Reduction of osteoclasts in a critical embryonic period is essential for inhibition of mouse tooth eruption. <i>Journal of Bone and Mineral Research</i>, 18(1), 108-116.</p>

